Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
458-24-2
Molecular formula
C12H16F3N
Molecular weight
231.26 g/mol
Drug class
Serotonergic antiseizure medicineserotonin-releasing agent and 5-HT receptor modulator
Mechanism of action
The precise mechanism by which fenfluramine reduces seizures in Dravet syndrome and Lennox-Gastaut syndrome is not fully established. It enhances serotonergic signalling, including activity at 5-HT receptors, and may also modulate sigma-1 receptor signalling.
Indications / reported uses
Treatment of seizures associated with Dravet syndrome in patients aged 2 years and older
Treatment of seizures associated with Lennox-Gastaut syndrome in patients aged 2 years and older; use requires product-specific cardiac monitoring because of valvular heart disease and pulmonary arterial hypertension risks
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Fenfluramine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Fenfluramine Permitted Daily Exposure (PDE) report (the Fenfluramine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Fenfluramine Occupational Exposure Limit (OEL) report (the Fenfluramine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.